

New appointments within Hybrigenics' Board of Directors

- **Dr. Alain Munoz elected Chairman of the Board of Directors**
- **Mr. Mogens Vang Rasmussen elected independent Director**

Paris, 01 July 2015 – Hybrigenics (ALHYG), a bio-pharmaceutical company listed on the Alternext market of Euronext Paris, with a focus on research and development of new treatments against proliferative diseases and specialized in proteomic and genomic scientific services, announces today the elections of Dr. Alain Munoz as Chairman of its Board and of Mr. Mogens Vang Rasmussen as an independent Director.

Dr. Munoz joined Hybrigenics' Board in 2011 as a Director especially in charge of clinical development (cf. Hybrigenics' press release of October 05, 2011). Now that inecalcitol enters a phase of clinical development both in Europe and the USA, Dr. Munoz replaces as Chairman Mr. Daan Ellens, who was not candidate for re-election after ten years of chairmanship.



Dr. Munoz has received his medical degrees as a physician specialized in cardiology, anaesthesiology and intensive care. He completed financial and management trainings at CRC (Jouy-en-Josas, France) and IMD (Lausanne, Switzerland). Dr. Munoz started his career as resident and then head of clinical department of cardiology at the University Hospital of Montpellier (France). Next, he joined Sanofi's research as head of the cardiovascular department, then project leader of the cardiovascular-antithrombotic range of products

before being appointed vice-president of international development. Later, he moved to the Fournier Group as vice-president for R&D, then senior vice-president in charge of the pharmaceutical division. In addition, he has been a member of the scientific committee of the French Drug Agency. Since 2000, Dr. Munoz has developed independent activities in the biopharmaceutical field: entrepreneur, Novagali Pharma's Chairman, Director of Erytech Pharma (ERYP.PA) and Auris Medical (EARS). Under his leadership, numerous drug product registrations were obtained world-wide such as *Adenocard*®, *Plavix*®, *Cordarone*®, *Tricor*™/*Lipanthyl*®, *Ikervis*® and *Esclim*®. He is also on the Board of several listed companies: Valneva (VLA.PA), Zealand Pharma (ZEAL.CO) and Gentical (GTCL.PA).



Mr. Vang Rasmussen holds a Master of Science in Economics from the University of Copenhagen and has followed several executive seminars from INSEAD and Stanford Business School. He started his career at Novo Nordisk in 1983 and held several positions in corporate controlling and investor relationships, first at the Danish headquarters and later in New-York for all North-American activities. In 1994, he joined Tele Danmark (now TDC) as vice-president, senior economist. In 1999, he moved to MediCult as CFO and was promoted CEO. From 2003 to 2010, Mr. Vang Rasmussen has worked at Zealand Pharma where he last was both CFO and COO. In 2010, he set up his firm, Ibenfeldt Consulting, and completed various long term transition CFO missions such as at Serodus A/S and Urodan ApS. Mr. Vang Rasmussen is a partner of Vesicon SAS in France and Chairman of the Board of Pila Pharma AB in Sweden.

"I would like to pay tribute to the outstanding ten years of Daan Ellens as Chairman. During this period, Hybrigenics, among other feats, has brought inecalcitol to Phase II clinical positioning as a potential oral treatment in all three adult leukemias and developed the scientific services activities into a profitable subsidiary," said Dr. Munoz, new Chairman of Hybrigenics' Board of Directors. *"The next progression stage for Hybrigenics faces two challenges which are also real opportunities for the company: the internationalization of the clinical development of inecalcitol and the sustained growth of the fee-for-service business. I thank my Board colleagues for their trust and I am confident in everyone's efforts at Hybrigenics, Directors, management and staff, to seize them."*

HYBRIGENICS

Press Release

About Hybrigenics

Hybrigenics (www.hybrigenics.com) is a bio-pharmaceutical group listed (ALHYG) on the Alternext market of Euronext Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of proliferative diseases and providing cutting-edge proteomic and genomic scientific services.

Hybrigenics' current development program is based on inecalcitol, a vitamin D receptor agonist active by oral administration. Oral inecalcitol has shown excellent tolerance and strong presumption of efficacy for the first-line treatment of metastatic castrate-resistant prostate cancer in combination with Taxotere®, which is the current gold-standard chemotherapeutic treatment for this indication. Inecalcitol has also been tested in chronic lymphocytic leukemia patients, an indication for which inecalcitol has received orphan drug status in Europe and the United States. A clinical Phase II study of inecalcitol is currently ongoing in chronic myeloid leukemia patients.

Hybrigenics has a research collaboration with Servier on deubiquitinating enzymes (DUBs) and their inhibitors in oncology, neurology, psychiatry, rheumatology, ophthalmology, diabetes and cardiovascular diseases. A first milestone has been achieved in a drug discovery program targeting one DUB in oncology. Hybrigenics Services (www.hybrigenics-services.com) is the market leader in Yeast Two-Hybrid (Y2H) and related services to identify, validate and inhibit protein interactions for researchers in all areas of life sciences, using its ISO 9001-certified high-throughput Y2H screening platform.

Helixio (www.helixio.com), Hybrigenics' genomic branch, provides state-of-the-art services specialized in DNA chips, DNA or RNA target enrichment and next generation sequencing with an Illumina NextSeq500. Hybrigenics Corp., based in Cambridge, Mass., is the American subsidiary of Hybrigenics.

HYBRIGENICS is listed on the Alternext market of Euronext Paris

ISIN: FR0004153930

Ticker: ALHYG



Hybrigenics

Rémi Delansorne
CEO
Tel.: +33 (0)1 58 10 38 00
investors@hybrigenics.com

NewCap.

Financial communication
Julien Perez / Pierre Laurent
Tel.: +33 (0)1 44 71 94 94
hybrigenics@newcap.fr